Legend's early-stage CAR-T on FDA hold after single patient dosed

A phase 1 trial for Legend Biotech’s CAR-T therapy just got underway last year, and, now, the FDA has told the company to hit the brakes.

Legend announced a clinical hold for LB1901 in a brief press release Tuesday morning. Prior to receiving the hold notice from the agency, the company voluntarily paused the trial after the first patient was dosed and experienced low CD4+ T-cell counts.